Chemours (CC) Stock Price, News & Analysis

Company Overview

The Chemours Company (NYSE: CC) is a global chemistry company headquartered in Wilmington, Delaware. Formed in 2015 through a spin-off from DuPont, Chemours develops and manufactures chemical products used in industries including transportation, electronics, energy, construction, and consumer goods.

The company operates through businesses focused on thermal and specialized solutions, titanium technologies, and advanced performance materials. Its products include refrigerants and heat-transfer fluids, titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper, as well as fluoropolymers, specialty fluids, and other performance materials used in demanding industrial applications.

Chemours serves customers in North America, Latin America, Europe, the Asia-Pacific region, and other international markets through manufacturing facilities, research and development operations, and commercial activities around the world. Denise Dignam serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $14.11 to $14.91
• 50-Day Range: $14.44 to $18.60
• 52-Week Range: $10.44 to $28.67
• Volume: 2.14 million shs
• Average Volume: 1.60 million shs
• Market Capitalization: $2.17 billion
• P/E Ratio: N/A
• Dividend Yield: 2.42%
• Price Target: $20.10
• Consensus Rating: Hold

Chemours Stock Analysis - MarketRank™

Chemours scored higher than 89% of companies evaluated by MarketBeat, and ranked 51st out of 230 stocks in the materials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Hold

Consensus Rating

Chemours has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 5 buy ratings, 6 hold ratings, and 1 sell rating.

Upside Potential

Chemours has a consensus price target of $20.10, representing about 39.2% upside from its current price of $14.44.

Amount of Analyst Coverage

Chemours has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 128.74%

Earnings Growth

Earnings for Chemours are expected to grow by 128.74% in the coming year, from $0.87 to $1.99 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chemours is -7.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chemours is -7.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Chemours has a P/B Ratio of 8.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.94% of the float of Chemours has been sold short.

Short Interest Ratio / Days to Cover

Chemours has a short interest ratio ("days to cover") of 9.25.

Change versus previous month

Short interest in Chemours has recently increased by 9.52%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Chemours pays a meaningful dividend of 2.38%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Chemours does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, Chemours will have a dividend payout ratio of 17.59% next year. This indicates that Chemours will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.33

News Sentiment

Chemours has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Materials companies.

News Coverage This Week

MarketBeat has tracked 19 news articles for Chemours this week, compared to 5 articles on an average week.

Search Interest

Only 1 people have searched for CC on MarketBeat in the last 30 days. This is a decrease of -95% compared to the previous 30 days.

MarketBeat Follows

4 people have added Chemours to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 3.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

3 insiders have purchased shares of Chemours in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $130,601.00 in company stock, which represents 0.0060% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Chemours insiders have bought more of their company's stock than they have sold. Specifically, they have bought $130,601.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

0.85% of the stock of Chemours is held by insiders.

Percentage Held by Institutions

76.26% of the stock of Chemours is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Record date for 9/15 Dividend: 8/14/2026
• Ex-Dividend for 9/15 Dividend: 8/14/2026
• Dividend Payable: 9/15/2026
• Today: 9/17/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Materials
• Industry: Chemicals
• Sub-Industry: Diversified Chemicals
• Current Symbol: NYSE:CC
• CIK: 1627223
• Web: www.chemours.com
• Phone: (302) 773-1000
• Fax: N/A
• Employees: 5,700
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Chemours: $20.10
• High Price Target: $30.00
• Low Price Target: $15.00
• Potential Upside/Downside: +39.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 16.59
• P/E Growth: N/A
• Net Income: -$386 million
• Net Margins: -5.00%
• Pretax Margin: -0.90%
• Return on Equity: 60.64%
• Return on Assets: 1.48%

Debt

• Debt-to-Equity Ratio: 18.98
• Current Ratio: 1.66
• Quick Ratio: 0.88

Sales & Book Value

• Annual Sales: $5.81 billion
• Price / Sales: 0.37
• Cash Flow: $3.24 per share
• Price / Cash Flow: 4.45
• Book Value: $1.67 per share
• Price / Book: 8.64

Miscellaneous

• Outstanding Shares: 150,500,000
• Free Float: 149,220,000
• Market Cap: $2.17 billion
• Optionable: Optionable
• Beta: 1.42